We are thrilled to join the Drug Discovery Biology & Medicinal Chemistry Strategy Meetings hosted by Proventa International at Cambridge, MA at Le Meridien Hotel. We are excited to share our insights and experiences in the drug discovery field with…
Learn how Pelago Bioscience and our technology CETSA®, Cellular Thermal Shift Assay can help you assess target engagement, and bring your projects forward with confidence through: • Physiologically relevant, robust data • Completely label-free • Transferability across matrices…
Protein degradation is a novel modality with the potential to tackle therapeutically interesting proteins previously seen as undruggable. In this area, CETSA® is a powerful technology for identifying binders, investigating target engagement and the mechanism of action of the protein…
In a recent collaboration between AbbVie Chemical Biology and Pelagoo Bioscience, CETSA® was applied to quantify direct target engagement of several inhibitors in unprocessed human whole blood. The study investigated RIPK1 as a proof-of-concept target, showcasing the high sensitivity and…
CETSA® by Pelago Bioscience is a well-proven, best-in-class technology used to assess cellular protein-compound binding in cell. CETSA® can be applied throughout all steps of the drug discovery value chain for screening, hit confirmation and selectivity. Because neither the ligand…
Pelago Bioscience proudly receives the HUPO Science and Technology Award, celebrating our pioneering work in CETSA (Cellular Thermal Shift Assay) and the Pelago team work including Alexey Chernobrovkin and Tomas Friman. This technology provides invaluable insights into proteomics, and how…
Impilo invests in Pelago Bioscience AB and enters a partnership to accelerate Pelago’s growth. Founded in 2013, Pelago is a fast-growing drug discovery focused contract research organisation offering services based on the patented CEllular Thermal Shift Assay (CETSA®) technology…
Webinar Overview In this webinar, you will find the details of the project where CETSA® Explore was leveraged to study the biological mechanism of the fungal polyketide lactone Brefeldin A (BFA) in human THP-1 cells. Fungal genomes encode a…
We are thrilled to share our latest publication in the journal “ACS Medicinal Chemistry Letters” titled – A Shift in Thinking: Cellular Thermal Shift Assay-Enabled Drug Discovery. In this study, we highlighted recently published applications of CETSA® and how the…
Pelago Bioscience is bringing together the CETSA® community to inspire, learn and unleash drug discovery. As Pelago is expanding its portfolio of services and technologies, we remain committed to empowering our partners in accelerating drug discovery. As a part…
The Cellular Thermal Shift Assay (CETSA®) is an easy and proven method to demonstrate ligand-protein interactions in living cells and can be used without the need of any modifications to the ligand or protein. Quantification methods like PerkinElmer’s no-wash immunoassays…
CETSA® by Pelago can be adapted for different applications to support any stage of the drug discovery process from low-throughput confirmation and high-throughput discovery to proteome-wide exploration – these methods rely on the same principle: measurements of the ‘thermal shift…
Pelago Bioscience AB expands to new facility After several years of continued growth in our current facilities Pelago Bioscience now really expands. The new building is located at Campus Solna, a rapidly developing Life Science cluster located in central…
Confirmation of target engagement in relevant physiological environment ensures successful drug discovery and the right project prioritization. By applying CETSA®, you can make better and more informed decisions at earlier stages in your drug discovery projects. Welcome to learn from…
Time to celebrate – For the third year in a row, Pelago has been awarded the prestigious DI Gasell prize by the Swedish daily business newspaper Dagens Industri. This prize recognizes the fastest growing Swedish companies, with less than 1…
We have the pleasure to announce that the French Ministry for Higher Education and Research has recognised Pelago Bioscience AB as an approved research and development service provider. This allows companies, subject to the French General Tax Code, to take…
Don’t miss this new interesting CETSA® paper published in Nature Protocols. https://www.nature.com/articles/s41596-020-0310-z Are you sure? Is you target compound really theraputic? Speak to our experts Learn how CETSA® can enable your project by talking to one of our Drug Discovery…
